Rituximab treatment in myasthenia gravis
Myasthenia gravis (MG) is a chronic autoimmune disease mediated by antibodies against post-synaptic proteins of the neuromuscular junction. Up to 10%–30% of patients are refractory to conventional treatments. For these patients, rituximab has been used off-label in the recent decades. Rituximab is a...
Na minha lista:
| Principais autores: | , |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Frontiers Media S.A.
2023-10-01
|
| 叢編: | Frontiers in Neurology |
| 主題: | |
| 在線閱讀: | https://www.frontiersin.org/articles/10.3389/fneur.2023.1275533/full |
| 標簽: |
沒有標簽, 成為第一個標記此記錄!
|